Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Neuroendocrine Tumors
A Real-World Observational Study of Somatostatin Analog Use and Costs in Canada
Read More
Neuroendocrine Tumors
Efficacy of Somatostatin Analog Monotherapy for Grade 3 GEP-NETs
Read More
Neuroendocrine Tumors
Carcinoid Syndrome Improvements in Patients Receiving Telotristat Ethyl: Findings from TELEPRO-II
Read More
Neuroendocrine Tumors
Safety in Patients with NETs Receiving Telotristat Ethyl with Peptide Receptor Radionuclide Therapy
Read More
Neuroendocrine Tumors
Efficacy of Telotristat Ethyl in Patients with Progressive NET Disease: Real-World Clinical Practice Experience
Read More
Neuroendocrine Tumors
Health-Related Quality-of-Life Results of Surufatinib in Advanced Extrapancreatic NETs (SANET-ep Trial)
Read More
Neuroendocrine Tumors
Efficacy and Safety of Surufatinib in NETs
Read More
Neuroendocrine Tumors
Subgroup Analysis by Ki67 and Primary Tumor Origins of the Phase 3 SANET-ep Study of Surufatinib
Read More
Neuroendocrine Tumors
Retreatment PRRT with 177Lu-DOTATATE in Patients with NETs: Multicenter, Real-World Experience
Read More
Neuroendocrine Tumors
Impact of Treatment Order and Combination on Mortality Outcomes in 177Lu-DOTATATE–Treated Patients with Metastatic GEP-NETs
Read More
1
2
3
4
Page 3 of 4
Results 21 - 30 of 31